{
    "clinical_study": {
        "@rank": "127670", 
        "arm_group": [
            {
                "arm_group_label": "Formulation C", 
                "arm_group_type": "Experimental", 
                "description": "Two formulations of the OTX Punctum Plug will be evaluated in this trial. The difference in formulations is the time required for degradation of the PEG hydrogel. The persistence of OTX Punctum Plug (Formulation C) is anticipated to be slightly shorter than the persistence of OTX Punctum Plug (Formulation D)."
            }, 
            {
                "arm_group_label": "Formulation D", 
                "arm_group_type": "Experimental", 
                "description": "Two formulations of the OTX Punctum Plug will be evaluated in this trial. The difference in formulations is the time required for degradation of the PEG hydrogel. The persistence of OTX Punctum Plug (Formulation C) is anticipated to be slightly shorter than the persistence of OTX Punctum Plug (Formulation D)."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate retention and replacement of the OTX Punctum Plug\n      when placed in the canaliculus of the eyelid.  Subjects will be followed for up to 1 year in\n      order to assess retention and replacement of the OTX Punctum Plug for this duration. At the\n      Day 90 visit, subjects will receive a second OTX Punctum Plug after removal of the initial\n      OTX Punctum Plug. The subject will return for visits at Day 180, 270 and 360.  On Days 180\n      and 270, the subject will again receive a new OTX Punctum Plug after the previous OTX\n      Punctum Plug is removed."
        }, 
        "brief_title": "Non-Significant Risk Feasibility Study to Assess Retention and Replacement of the OTX Punctum Plug", 
        "condition": "Healthy Subjects", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject must be greater than or equal to 40 years of age.\n\n          -  Subject is in general good health with overall healthy eyes.\n\n          -  Subject has been informed of the nature of the study and is able to comply  with\n             study requirements, the visit schedule and has provided written informed consent,\n             approved by the appropriate IRB.\n\n        Exclusion Criteria:\n\n          -  Presence of any uncontrolled systemic or debilitating disease (e.g. cardiovascular\n             disease, hypertension, diabetes, or cystic fibrosis).\n\n          -  History of ocular trauma within the past 6 months in either eye.\n\n          -  History of ocular infection (bacterial, viral, or fungal) or ocular inflammation\n             within 3 months prior to the study in either eye.\n\n          -  History of chronic or recurrent inflammatory eye disease (i.e., iritis, scleritis,\n             uveitis, herpes keratitis) in either eye.\n\n          -  History of clinically relevant or progressive retinal diseases such as retinal\n             detachment, retinal degeneration, or diabetic retinopathy in either eye.\n\n          -  History of any other severe ocular pathology (including severe dry eye) in either\n             eye.\n\n          -  History of any laser or incisional surgery within 6 weeks prior to the study or\n             scheduled ocular surgery during the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01800175", 
            "org_study_id": "OTX-13-001"
        }, 
        "intervention": {
            "arm_group_label": [
                "Formulation C", 
                "Formulation D"
            ], 
            "intervention_name": "Punctum Plug", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "February 26, 2013", 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "vfaughnan@ocutx.com", 
            "last_name": "Veronica Faughnan", 
            "phone": "781-357-4010"
        }, 
        "overall_contact_backup": {
            "email": "dmulani@ocutx.com", 
            "last_name": "Deepa Mulani", 
            "phone": "781-357-4023"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Retention of the first OTX Punctum Plug through Day 90, retention of the second OTX Punctum Plug through Day 180, retention of the third OTX Punctum Plug through Day 270, retention of the fourth OTX Punctum Plug through Day 360", 
            "measure": "Punctum Plug retention for 90 days post insertion", 
            "safety_issue": "Yes", 
            "time_frame": "360 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01800175"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Successful insertion of a replacement OTX Punctum Plug at Days 90, 180 and 270", 
            "safety_issue": "Yes", 
            "time_frame": "270 days"
        }, 
        "source": "Ocular Therapeutix, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ocular Therapeutix, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}